Reversibility of lipoatrophy associated with highly active antiretroviral therapy 1 year after switching from stavudine to tenofovir disoproxil fumarate

被引：0
|
作者：
Tsekes, G
Tsogas, N
Mangafas, N
Koukios, D
Michalakeas, C
Feretis, A
Lazanas, MC
机构：
[1] Red Cross Hosp, Dept Internal Med 3, Athens, Greece
[2] Red Cross Hosp, Infect Dis Unit, Athens, Greece
[3] Red Cross Hosp, Dept Radiol, Athens, Greece
来源：
ANTIVIRAL THERAPY | 2004年 / 9卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
047
引用
收藏
页码：L30 / L30
页数：1
相关论文
共 50 条
  • [1] Body composition changes in HIV-infected patients with lipoatrophy 1 and 2 years after switching from stavudine to tenofovir disoproxil fumarate
    Tsekes, G
    Chini, M
    Tsogas, N
    Mangafas, N
    Lioni, A
    Salpigktis, I
    Delikanakis, N
    Lazanas, MC
    [J]. ANTIVIRAL THERAPY, 2005, 10 (08) : L26 - L27
  • [2] Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: Reversion after switching (Stavudine to tenofovir and Lopinavir/Ritonavir to Atazanavir/Ritonavir)
    Domingos, Hamilton
    da Cunha, Rivaldo Venancio
    Paniago, Anamaria Mello Miranda
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (02): : 290 - 292
  • [3] The 10-year safety and efficacy of a tenofovir disoproxil fumarate (TDF)-containing, once-daily highly active antiretroviral therapy (HAART)
    Herath, C.
    Cassetti, I.
    Madruga, J. V.
    Etzel, A.
    Suleiman, J. M.
    Zhou, Y.
    Rhee, M.
    Warren, D. R.
    [J]. HIV MEDICINE, 2011, 12 : 74 - 74
  • [4] A pathogenesis proposal of lipoatrophy reversibility after switching from thymidine analogues to tenofovir
    Milinkovic, A.
    Garcia, A. I.
    Perez, I.
    Vidal, S.
    Ayuso, C.
    Laguno, M.
    Leon, A.
    Blanco, J. L.
    Martinez, M.
    Lonca, M.
    Larrousse, M.
    Martinez, E.
    Gatell, J. M.
    Tomas, X.
    Mallolas, J.
    [J]. ANTIVIRAL THERAPY, 2008, 13 (08) : A49 - A49
  • [5] Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy
    Winston, A
    Amin, J
    Mallon, PWG
    Marriott, D
    Carr, A
    Cooper, DA
    Emery, S
    [J]. HIV MEDICINE, 2006, 7 (02) : 105 - 111
  • [6] Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate
    Kaneko, Shun
    Kurosaki, Masayuki
    Tamaki, Nobuharu
    Itakura, Jun
    Hayashi, Tsuguru
    Kirino, Sakura
    Osawa, Leona
    Watakabe, Keiya
    Okada, Mao
    Wang, Wan
    Shimizu, Takao
    Higuchi, Mayu
    Takaura, Kenta
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Takahashi, Yuka
    Watanabe, Mamoru
    Izumi, Namiki
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (11) : 2004 - 2010
  • [7] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
    Gane, Edward
    Seto, Wai Kay
    Janssen, Harry L. A.
    Caruntu, Florin A.
    Kim, Hyung Joon
    Abdurakhmanov, Dzhamal
    Nishiguchi, Shuhei
    Horban, Andrzej
    Bae, Ho
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Oberle, Corinna
    Mo, Shuyuan
    Subramanian, G. Mani
    Kao, Jia-Horng
    Brunetto, Maurizia
    Buti, Maria
    [J]. SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
  • [8] BONE AND RENAL SAFETY ARE IMPROVED IN CHRONIC HBV PATIENTS 1 YEAR AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Chan, Henry Lik Yuen
    Seto, Wai Kay
    Buti, Maria
    Izumi, Namiki
    Lim, Young-Suk
    Kao, Jia-Horng
    Streinu-Cercel, Adrian
    Nurmukhametova, Elena
    Ma, Xiaoli
    Tabak, Fehmi
    Jablkowski, Maciej
    Suri, Vithika
    Flaherty, John
    Lau, Audrey
    Gaggar, Anuj
    Mo, Shuyuan
    Chowdhury, Abhijit
    Fung, Scott
    Chuang, Wan-Long
    Gane, Edward
    [J]. GUT, 2019, 68 : A141 - A142
  • [9] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
    Janssen, H.
    Gane, E.
    Seto, W-K
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Horban, A.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J.
    Kao, J-H
    Brunetto, M.
    Ferret, M. B.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
  • [10] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
    Seto, Wai Kay Walter
    Buti, Maria
    Izumi, Namiki
    Lim, Young-Suk
    Kao, Jia-Horng
    Streinu-Cercel, Adrian
    Nurmukhametova, Elena
    Ma, Xiaoli
    Tabak, Fehmi
    Jablkowski, Maciej
    Suri, Vithika
    Flaherty, John F.
    Lau, Audrey H.
    Gaggar, Anuj
    Mo, Shuyuan
    Chowdhury, Abhijit
    Fung, Scott K.
    Chuang, Wan-Long
    Gane, Edward J.
    [J]. HEPATOLOGY, 2018, 68 : 240A - 241A
12345